As biopharma companies eye product launches in a commercial environment that has been transformed by the COVID-19 pandemic, they must adjust their launch preparations to account for a more complex, fragmented and dynamic landscape. In Pharmaceutical Executive, Kevin Frymire, Dan Schulman and David Laros explain how companies can embrace launch agility.
Read Full Article